ENTRY       D04687                      Drug
NAME        Lenalidomide (JAN/USAN/INN);
            Revlimid (TN)
PRODUCT     REVLIMID (Celgene Corporation)
  GENERIC   LENALIDOMIDE (Alvogen)
            LENALIDOMIDE (Apotex Corp.)
            LENALIDOMIDE (Aurobindo Pharma Limited)
            LENALIDOMIDE (Camber Pharmaceuticals)
            LENALIDOMIDE (Cipla USA)
            LENALIDOMIDE (Cipla USA)
            LENALIDOMIDE (Dr. Reddy's Laboratories)
            LENALIDOMIDE (Exelan Pharmaceuticals)
            LENALIDOMIDE (Mylan Pharmaceuticals)
            LENALIDOMIDE (Sun Pharmaceutical Industries)
            LENALIDOMIDE (Teva Pharmaceuticals)
            LENALIDOMIDE (Teva Pharmaceuticals)
            LENALIDOMIDE (Zydus Lifesciences Limited)
            LENALIDOMIDE (Zydus Pharmaceuticals USA)
FORMULA     C13H13N3O3
EXACT_MASS  259.0957
MOL_WEIGHT  259.2606
CLASS       Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drug (DMARD)
              DG01936  TNF inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L04AX04
            Chemical structure group: DG00744
            Product (DG00744): D04687<JP/US> D09813<JP>
EFFICACY    Antineoplastic, Immunomodulator, TNF-alpha inhibitor
  DISEASE   Multiple myeloma [DS:H00010]
            Myelodysplastic syndromes (chromosome 5q deletion) [DS:H01484]
            Mantle cell lymphoma [DS:H01464]
            Follicular lymphoma [DS:H01613]
COMMENT     Thalidomide [DR:D00754] derivative
TARGET      TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
  PATHWAY   hsa04060(7124)  Cytokine-cytokine receptor interaction
            hsa04064(7124)  NF-kappa B signaling pathway
            hsa04210(7124)  Apoptosis
            hsa04640(7124)  Hematopoietic cell lineage
            hsa04650(7124)  Natural killer cell mediated cytotoxicity
            hsa04668(7124)  TNF signaling pathway
INTERACTION  
STR_MAP     map07046  Immunosuppressive agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AX Other immunosuppressants
                 L04AX04 Lenalidomide
                  D04687  Lenalidomide (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Immunomodulatory Agents
               Lenalidomide
                D04687  Lenalidomide (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D04687  Lenalidomide (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               DG01936  TNF inhibitor
                DG00744  Lenalidomide
                 D04687  Lenalidomide
            Drug classes [BR:br08332]
             Immunological agent
              DG01936  TNF inhibitor
               D04687  Lenalidomide
             Antirheumatic agent
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D04687  Lenalidomide
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Tumor necrosis factors
                TNF (TNFA, TNFSF2)
                 D04687  Lenalidomide (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D04687
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D04687
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D04687
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D04687
            Drug groups [BR:br08330]
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               DG01936  TNF inhibitor
                DG00744  Lenalidomide
DBLINKS     CAS: 191732-72-6
            PubChem: 47206522
            ChEBI: 63791
            LigandBox: D04687
            NIKKAJI: J1.121.689G
ATOM        19
            1   C8x C    12.8800  -15.7500
            2   C8x C    12.8800  -17.1500
            3   C8x C    14.0924  -17.8500
            4   C8y C    15.3049  -17.1500
            5   C8y C    15.3049  -15.7500
            6   C8y C    14.0924  -15.0500
            7   C5x C    16.6364  -17.5826
            8   N1y N    17.4593  -16.4500
            9   C1x C    16.6364  -15.3174
            10  C1y C    18.8300  -16.4500
            11  O5x O    17.0675  -18.9094
            12  N1a N    14.0924  -13.6502
            13  C1x C    19.5300  -17.6624
            14  C1x C    20.9300  -17.6624
            15  C5x C    21.6300  -16.4500
            16  N1x N    20.9300  -15.2376
            17  C5x C    19.5300  -15.2376
            18  O5x O    18.8396  -14.0421
            19  O5x O    23.0300  -16.4500
BOND        21
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 1
            9     8   9 1
            10    5   9 1
            11    8  10 1
            12    7  11 2
            13    6  12 1
            14   10  13 1
            15   13  14 1
            16   14  15 1
            17   15  16 1
            18   16  17 1
            19   10  17 1
            20   17  18 2
            21   15  19 2
///
